MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202617092784 A) filed by Cedars-Sinai Medical Center on July 30, 2026, for Enhanced Regulatory T Cells And Methods Of Use Thereof.
Inventors include Marbn, Eduardo; and Liao, Ke.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: Methods and compositions for treating fibrosis (e.g., cardiac fibrosis), or other conditions associated with inflammation and/or fibrosis are provided. Methods can include administering a nucleic acid encoding a sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein to a subject in need of fibrosis treatment, where the Siglec-9 protein is expressed by the nucleic acid in regulatory T (Treg) cells in the subject. Methods and compositions can include Treg cells that overexpress Siglec-9 to enhance the ability of Treg cells to target cells expressing amine oxidase, copper containing 3 (AOC3), including fibroblasts or myofibroblasts. In some embodiments, the enhanced Treg cells are targeted to myofibroblasts (e.g., cardiac myofibroblasts) with elevated expression of fibrotic genes.
Disclaimer: Curated by HT Syndication.
